 Estrogen has been shown to reduce the risk of cardiovascular disease in women during their reproductive years. Estrogen binds to two types of receptors, ER and ER, as well as a newly discovered receptor called GPR30. It can also exert both genomic and non-genomic effects, such as reducing oxidative stress, fibrosis, angiogenesis, and vascular function. Additionally, it has been found to be beneficial in preventing or treating cardiovascular diseases in women. However, there are some concerns regarding the potential side effects of estrogen therapy, including from bosses, cancer, and arrhythmias. Recent research suggests that targeting specific ERs in the cardiovascular system could lead to new and potentially safer treatments for cardiovascular protection. This article was authored by Andrea Iorga, Christine M. Cunningham, Cheyenne Mowazeni, and others.